Illumina has delivered consistent revenue growth, with 4Q: data showing a steady increase from $5.7B in Q4 2024 to $6.5B in the most recent Q4 2025. More impressively, the company has expanded its net margins from 21.5% in Q4 2024 to 23.4% in Q4 2025, demonstrating strong operational discipline. Free cash flow generation has also remained robust, rising from $3.5B in Q4 2024 to $4.3B in the latest quarter. This combination of top-line growth, margin expansion, and healthy cash flow generation is particularly noteworthy given the challenging macroeconomic backdrop. Many companies have struggled with inflationary pressures, supply chain disruptions, and weaker demand, but Illumina appears to be navigating these headwinds effectively. The company's leading position in the genomics space, expanding installed base, and prudent cost management seem to be underpinning its resilience. While Illumina's shares have pulled back somewhat along with the broader market, the company's fundamental performance suggests the current valuation may not fully reflect its long-term growth potential. With continued execution and an improving macroeconomic environment, I see upside potential for Illumina's stock price over the next 6-12 months.

Research these companies